Insulet’s PODD robust execution to expand the Omnipod 5 platform globally is a tailwind. The company is also capitalizing on the significant growth opportunities in the Type 2 diabetes space. PODD ...
Insulet PODD appears well-positioned on solid prospects in the diabetes market. The company is progressing well with respect to product innovation and geographic expansion. The stock carries a Zacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback